Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price?
Amgen (AMGN) reported 10% revenue growth in Q2, with Tezspire sales up 42%. However, earnings per share rose just 4%, raising questions about earnings growth. The company's newer drugs, like Repatha and Imdelltra, drove growth, but older drugs face biosimilar competition. MariTide, an obesity drug, is a key focus for future earnings.
How this was made
The 30-second read
Why it matters
The mixed financial performance and positive trial data create a nuanced market reaction, balancing short‑term earnings concerns with long‑term growth potential.
Market read
The article provides fresh trial results and earnings dynamics that could influence biotech equities.
What to watch
Potential pricing pressure from biosimilars on older products may further strain margins.
Background
Amgen, a Dow component, posted strong sales growth but earnings lag, while both Amgen and AstraZeneca disclosed new Phase 3 data for Tezspire.
Ticker impact
Amgen reported Q2 sales up 10% while adjusted EPS rose only 4%, and disclosed Phase 3 trial results for Tezspire.
likely pressure as the market prices in slower earnings growth, with potential upside from the successful trial.
Earnings growth lag is a near‑term drag, while new Phase 3 data could boost long‑term expectations.
AstraZeneca, alongside Amgen, announced Phase 3 results for Tezspire in eosinophilic esophagitis.
likely modest upside as investors price in the new indication.
The trial success expands Tezspire's market potential, which could improve revenue outlook.
Market effects
Biotech sector may see broader optimism for eosinophilic esophagitis treatments.
U.S. pharma stocks could experience modest movement.
International investors tracking biotech pipelines may adjust exposure.
Counterpoint
The earnings lag could outweigh trial optimism, leading to short‑term downside.
Key entities
- companyAmgen
US‑listed biotech firm (NASDAQ:AMGN).
- companyAstraZeneca
US‑listed pharmaceutical company (NASDAQ:AZN).
